| Abstract: |
Purpose: There currently is no therapy that enhances the survival of patients with distantly metastatic squamous cell carcinoma (SCC). Engineered herpes oncolytic viruses are effective therapeutic agents when delivered directly to tumors in animal models, but their efficacy in treating disseminated disease is poorly defined. Experimental Design: We treated disseminated pulmonary SCC in mice with an interleukin (IL)-12-expressing oncolytic herpes virus (NV1042) or with the parent oncolytic virus (NV1023, IL-12 deficient) by i.v. tail vein administration. Results: Lung IL-12 was 16.1 pg/mg and IFN-γ was 4.3 pg/mg at day 1 after a single dose of NV1042 (5 × 107 plaque-forming units); levels of both were undetectable for NV1023.5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside histochemistry demonstrated viral infection of disseminated pulmonary tumor nodules by both vectors at day 1, with sparing of adjacent alveolar cells. NV1042-treated lungs showed no surface nodules at day 12, in contrast to NV1023-treated (92 ± 27 surface nodules) and PBS-treated (225 ± 9 surface nodules) lungs. Significantly enhanced survival was observed in NV1042-treated animals compared with NV1023- and PBS-treated animals (log rank < 0.05). In animals with a low tumor burden, 100% of NV1042-treated, 70% of NV1023-treated, and none of the control animals achieved long-term survival. NV1042 efficacy was similar to NV1023 efficacy in animals depleted of CD4/CD8 T lymphocytes, showing that IL-12 expression enhances oncolytic activity through immune effects. Histology showed no cytopathic effects in non-tumor-bearing lung, brain, spleen, liver, and pancreas after completion of viral therapy. No animals demonstrated any visible side effects attributable to viral therapy. Conclusions: The i.v. delivery of an oncolytic herpes virus may achieve effective infection, oncolysis, and transgene expression at distant tumor sites. This approach to systemic therapy combining oncolysis with IL-12 immune stimulation led to significantly improved survival in animals with disseminated SCC. |
| Keywords: |
cancer survival; controlled study; treatment outcome; survival rate; unclassified drug; squamous cell carcinoma; carcinoma, squamous cell; drug efficacy; nonhuman; cd8 antigen; t lymphocyte; cd8-positive t-lymphocytes; animal cell; mouse; animals; mice; lung neoplasms; animal experiment; animal model; tumor cells, cultured; lung metastasis; immune response; cd4-positive t-lymphocytes; gene therapy; oncolytic virus; cytokine production; herpesvirus 1, human; cd4 antigen; virus replication; virus strain; interleukin 12; injections, intravenous; mice, inbred c3h; defective viruses; interleukin-12; interferon type ii; lung alveolus cell; herpesvirus vector; male; priority journal; article; 5 bromo 4 chloro 3 indolyl beta dextro galactopyranoside; pyranoside
|
